Biopharmaceuticals, or biologics, are large-protein molecules derived from genetically modified cell lines. (In contrast, "traditional" pharmaceuticals are made from small-molecule, chemical substances.) A growing number of proprietary biopharmaceuticals' patents are expiring; and similar biologics are opening a large, emerging market. Hospira has significantly invested in expanding its comprehensive competencies to develop, manufacture and market similar biologics.
The European Commission approves similar biologics that demonstrate quality, efficacy and safety that are similar to currently available biopharmaceuticals in the approved indications. It has already approved other similar biologics. A comparable legal and regulatory approval pathway does not yet exist in the United States.
STADA Arzneimittel AG, headquartered in Bad Vilbel, Germany, is an international pharmaceutical company with a focus on generic and non-patented branded pharmaceutical products. STADA is one of the leading generic companies in Germany and in the European Union. It is listed on the Frankfurt Stock Exchange. STADA's news releases and other information can be found at http://www.stada.com.
Initiated by STADA and located in Bad Vilbel, Germany, BIOCEUTICALS Arzneimittel AG is focused on the development of biosimilar products. BIOCEUTICALS is predominantly financed via venture capital and is not quoted on a stock exchange.
Hospira, Inc. is a global specialty pharmaceutical and medication
delivery company dedicated to Advancing Wellness(TM) by developing,
manufacturing and marketing products that help improve the productivity,
safety and efficacy of patient care. In February 2007, Hospira acquired
Mayne Pharma Limited to become the world leader in specialty generic
injectable pharmaceuticals. With 70 years of service to the
|SOURCE Hospira, Inc.|
Copyright©2007 PR Newswire.
All rights reserved